Literature DB >> 9350914

Beneficial effect of intracoronary verapamil on microvascular and myocardial salvage in patients with acute myocardial infarction.

Y Taniyama1, H Ito, K Iwakura, T Masuyama, M Hori, S Takiuchi, N Nishikawa, Y Higashino, K Fujii, T Minamino.   

Abstract

OBJECTIVES: We assessed the acute effect of intracoronary injection of verapamil on microvascular function after primary percutaneous translumanal coronary angioplasty (PTCA) for acute myocardial infarction (AMI) with myocardial contrast echocardiography (MCE) in relation to functional outcomes.
BACKGROUND: Recent clinical studies have documented the potential of verapamil for possible increase in coronary blood flow after primary PTCA.
METHODS: Forty patients with a first AMI were randomly assigned to the verapamil group (n = 20) or the control group (n = 20). In the verapamil group, verapamil (0.5 mg) was injected into the infarct-related artery shortly after PTCA, followed by the oral administration. We performed MCE with an intracoronary injection of sonicated microbubbles before and after verapamil. To assess microvascular integrity, we determined the baseline-subtracted peak intensity in the risk area and the ratio of the no reflow zone plus the low reflow zone to the risk area (low reflow ratio). We determined the average wall motion score (dyskinesia/akinesia = 3; normal = 0) in the risk area on the day of AMI and a mean of 24 days later.
RESULTS: The low reflow zone was observed shortly after PTCA in 14 verapamil group patients, and the low reflow ratio decreased after verapamil (0.39 +/- 0.23 vs. 0.29 +/- 0.17 [mean +/- SD], p < 0.05). Peak intensity significantly (p < 0.05) increased from 6 +/- 5 to 12 +/- 6 after verapamil. The reduction in wall motion score from the acute (day -1) to the late stage (day -24) was significantly greater in the verapamil group than in the control group (0.7 +/- 0.8 vs. 0.2 +/- 1.3, respectively, p < 0.05).
CONCLUSIONS: Intracoronary administration of verapamil after primary PTCA can attenuate microvascular dysfunction and thereby augment myocardial blood flow in patients with AMI, leading to better functional outcome than with PTCA alone.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9350914     DOI: 10.1016/s0735-1097(97)00277-5

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  32 in total

Review 1.  The "no-reflow" phenomenon: basic science and clinical correlates.

Authors:  Thorsten Reffelmann; Robert A Kloner
Journal:  Heart       Date:  2002-02       Impact factor: 5.994

2.  Optimal therapeutic strategies in the setting of post-infarct no reflow: the need for a pathogenetic classification.

Authors:  L Galiuto
Journal:  Heart       Date:  2004-02       Impact factor: 5.994

Review 3.  Management of microvascular dysfunction and reperfusion injury.

Authors:  A Prasad; B J Gersh
Journal:  Heart       Date:  2005-12       Impact factor: 5.994

4.  Coronary No-reflow Phenomenon.

Authors:  Shereif H Rezkalla; Robert A Kloner
Journal:  Curr Treat Options Cardiovasc Med       Date:  2005-05

5.  The role of vasodilators in the prevention and treatment of no-reflow following percutaneous coronary intervention.

Authors:  S A Harding
Journal:  Heart       Date:  2006-04-10       Impact factor: 5.994

6.  Potential of microvascular reperfusion with adjunctive pharmacological intervention: its impact on myocardial perfusion and functional outcomes in patients with acute myocardial infarction.

Authors:  Y Taniyama; H Ito; R Morishita; T Ogihara
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 7.  Intracoronary pharmacotherapy in the management of coronary microvascular dysfunction.

Authors:  Vijayalakshmi Kunadian; Cafer Zorkun; Scott P Williams; Leah H Biller; Alexandra M Palmer; Katherine J Ogando; Michelle E Lew; Navin Nethala; William J Gibson; Susan J Marble; Jacqueline L Buros; C Michael Gibson
Journal:  J Thromb Thrombolysis       Date:  2008-09-26       Impact factor: 2.300

Review 8.  A role for pericytes in coronary no-reflow.

Authors:  Fergus M O'Farrell; David Attwell
Journal:  Nat Rev Cardiol       Date:  2014-04-29       Impact factor: 32.419

9.  Impact of advanced age on myocardial perfusion, distal embolization, and mortality patients with ST-segment elevation myocardial infarction treated by primary angioplasty and glycoprotein IIb-IIIa inhibitors.

Authors:  Giuseppe De Luca; Arnoud W J van't Hof; Kurt Huber; C Michael Gibson; Francesco Bellandi; Hans-Richard Arntz; Mauro Maioli; Marko Noc; Simona Zorman; Gioel Gabrio Secco; Uwe Zeymer; H Mesquita Gabriel; Ayse Emre; Donald Cutlip; Tomasz Rakowski; Maryann Gyongyosi; Dariusz Dudek
Journal:  Heart Vessels       Date:  2013-03-14       Impact factor: 2.037

10.  Intraarterially administered verapamil as adjunct therapy for cerebral vasospasm: safety and 2-year experience.

Authors:  Lei Feng; Brian-Fred Fitzsimmons; William L Young; Mitchell F Berman; Erwin Lin; Beverly D L Aagaard; Hoang Duong; John Pile-Spellman
Journal:  AJNR Am J Neuroradiol       Date:  2002-09       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.